QCM
NTLA icon

Quantinno Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Quantinno Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$663K Sell
39,191
-518
-1% -$7.25K ﹤0.01% 2831
2026
Q1 		$509K Buy
39,709
+6,266
+19% +$79.8K ﹤0.01% 2702
2025
Q4 		$301K Buy
33,443
+9,145
+38% +$126K ﹤0.01% 2830
2025
Q3 		$420K Buy
24,298
+4,669
+24% +$57.5K ﹤0.01% 2175
2025
Q2 		$184K Buy
19,629
+8,185
+72% +$67.2K ﹤0.01% 2385
2025
Q1 		$81.4K Buy
+11,444
New +$116K ﹤0.01% 2061

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Quantinno Capital Management's NTLA Position: Q2 2026 in Review

Quantinno Capital Management reduced its Intellia Therapeutics (NTLA) stake by 1.3% in Q2 2026, selling an estimated $7.25K and leaving 39,191 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #2831.

Quantinno Capital Management first reported a position in NTLA in Q1 2025 and has held it in 6 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Quantinno Capital Management held 39,191 shares of Intellia Therapeutics worth $663K as of Q2 2026.
  • Quantinno Capital Management sold 518 Intellia Therapeutics shares in Q2 2026, an estimated $7.25K.
  • Intellia Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2831 holding.
  • Quantinno Capital Management first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.